rasburicase

CLINICAL USE

Prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy for haematological malignancy

DOSE IN NORMAL RENAL FUNCTION

200 mcg/kg once daily for up to 7 days

PHARMACOKINETICS

Molecular weight :34 000

%Protein binding :0

%Excreted unchanged in urine : 0

Volume of distribution (L/kg) :0.11–0.127

half-life – normal/ESRD (hrs) :19/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

With solvent provided

Route

Rate of Administration

Over 30 minutes

Comments

Add appropriate volume to 50 mL sodium chloride 0.9%

OTHER INFORMATION

Renal elimination of rasburicase is considered to be a minor pathway for rasburicase clearanceRasburicase is a protein; it is expected that metabolic degradation will follow the pathways of other proteins, i.e. peptide hydrolysisAfter infusion of rasburicase at a dose of 0.20 mg/kg/day, steady state is achieved at day 2–3.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home